Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,378 across all filing types
Latest filing 2020-01-24 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - CSTONE SUCCESSFULLY HOSTED THE FIRST U.S. R&D DAY IN NEW YORK
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals about hosting a U.S. R&D Day event. It provides detailed updates on the company's research and development pipeline, clinical trials, milestones expected in 2020, and strategic plans for transitioning from a clinical-stage to a commercial-stage biopharmaceutical company. The content focuses on business updates, clinical development progress, and future plans rather than presenting financial statements or regulatory filings. There is no indication that this is an official financial report, audit report, earnings release, or regulatory filing. The document is an announcement of company progress and strategy, typical of a voluntary corporate announcement or investor relations update. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2020-01-24 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT DOSED IN THE GLOBAL PROOF-OF-CONCEPT STUDY OF CS1001 IN COMBINATION WITH BAYER'S REGORAFENIB
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals about dosing the first patient in a global proof-of-concept clinical study combining their investigational drug CS1001 with Bayer's regorafenib. It discusses the clinical trial design, drug background, collaboration details, and company information. There are no financial statements, regulatory certifications, voting results, or management changes. The content is focused on clinical trial progress and collaboration news, typical of a corporate announcement rather than a financial or regulatory filing. The document length is 8463 characters, which is substantial but the content is clearly an announcement of a clinical trial milestone. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2020-01-23 English
ANNOUNCEMENT ON THE UNAUDITED MAJOR OPERATIONAL DATA OF THE FOURTH QUARTER OF 2019
Regulatory Filings Classification · 90% confidence The document is titled as an announcement on the unaudited major operational data for the fourth quarter of 2019. It provides specific operational data such as production and sales volumes for coal and coal chemicals businesses, but it explicitly states the data is unaudited and influenced by various factors. The document is relatively short (2865 characters) and is presented as an announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a voluntary announcement of operational data, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-01-22 English
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE FOURTH QUARTER OF 2019 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANZHOU COAL MINING COMPANY LIMITED
Report Publication Announcement Classification · 95% confidence The document is a short announcement (2521 characters) from Yanzhou Coal Mining Company Limited regarding the production and sales volume for the fourth quarter of 2019 of its overseas subsidiary, Yancoal Australia. It provides summary data and refers readers to the full reports published by Yancoal Australia on the ASX and HKEX websites for further details. The document does not contain detailed financial statements or comprehensive analysis, but rather a brief update with a link to the full report. According to the 'Menu vs Meal' rule, such a brief announcement that points to a full report elsewhere should be classified as a Report Publication Announcement (RPA), not as the full report itself (e.g., IR or 10-K).
2020-01-16 English
VOLUNTARY ANNOUNCEMENT - CSTONE'S PARTNER BLUEPRINT MEDICINES ANNOUNCED AYVAKIT (AVAPRITINIB) APPROVED BY THE US FDA FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC PDGFRA EXON 18 MUT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the FDA approval of a drug (avapritinib) developed in partnership with Blueprint Medicines. It discusses the drug approval, ongoing clinical trials, and future plans for submission of a new drug application in China. The document does not contain financial statements, detailed financial performance, or regulatory certifications. It is an announcement of a significant corporate event related to drug approval and partnership progress, not a financial report or regulatory filing. The length is about 5,490 characters, and it is clearly an announcement rather than a full report or transcript. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2020-01-15 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2020-01-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.